---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-110797"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:40:52.654595+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aziyo Biologics appoints David Colpman to board; regains Nasdaq audit committee compliance

## Summary
- David Colpman appointed to Board of Directors and audit committee effective Oct. 20, 2022; board size increased to six.
- Colpman brings over 25 years of healthcare business development experience, including senior roles at Shire, Novo Nordisk, Glaxo Wellcome.
- Appointment resolves Nasdaq noncompliance with Rule 5605(c)(2) (audit committee independence deficiency) created by Dr. Mills' role change.
- Colpman currently serves as advisor to HighCape Capital, affiliate of HighCape Partners, a controlling stockholder of Aziyo.
- CEO Dr. Randy Mills highlights Colpman's transaction experience as valuable for strategic partnerships and near-term priorities.

## SEC filing metadata
- accession: 0001104659-22-110797
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/0001104659-22-110797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/tm2228791d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-110797
- JSON: https://secwatch.observer/filing/0001104659-22-110797.json
- Plain text: https://secwatch.observer/filing/0001104659-22-110797.txt

## Key facts
- Executive change
  David Colpman was appointed as Director at ELUTIA INC..
  - Action: appointed
  - Role: Director
  source text: the Company) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/0001104659-22-110797-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.